Immunic (IMUX)
(Delayed Data from NSDQ)
$1.51 USD
+0.02 (1.34%)
Updated Aug 30, 2024 04:00 PM ET
After-Market: $1.51 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value A Growth D Momentum C VGM
Brokerage Reports
0 items in cart
Immunic, Inc. [IMUX]
Reports for Purchase
Showing records 1 - 20 ( 214 total )
Company: Immunic, Inc.
Industry: Medical - Biomedical and Genetics
Company: Immunic, Inc.
Industry: Medical - Biomedical and Genetics
Q4/FY23: Continuing to Advance IMU-838 Toward MS Readouts in 2025 2026
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: Immunic, Inc.
Industry: Medical - Biomedical and Genetics
Q3 Financials; Continued Execution Heading into 2024
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: Immunic, Inc.
Industry: Medical - Biomedical and Genetics
Company: Immunic, Inc.
Industry: Medical - Biomedical and Genetics
Flashing (Neurofilament) Lights; IMU-838 Shows Impact on NfL Biomarker in PMS
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: Immunic, Inc.
Industry: Medical - Biomedical and Genetics
Company: Immunic, Inc.
Industry: Medical - Biomedical and Genetics
Company: Immunic, Inc.
Industry: Medical - Biomedical and Genetics
Company: Immunic, Inc.
Industry: Medical - Biomedical and Genetics
Q2: Eyes on Interim Ph2 Results for IMU-838/PMS in the Fall; Pipeline Updates
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: Immunic, Inc.
Industry: Medical - Biomedical and Genetics
Company: Immunic, Inc.
Industry: Medical - Biomedical and Genetics
Celiac Disease Roundtable Takeaways; Focus Remains on Upcoming MS Readouts
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: Immunic, Inc.
Industry: Medical - Biomedical and Genetics
Company: Immunic, Inc.
Industry: Medical - Biomedical and Genetics
Company: Immunic, Inc.
Industry: Medical - Biomedical and Genetics
Company: Immunic, Inc.
Industry: Medical - Biomedical and Genetics
IMU-856''s MOA Revealed at DDW; Near-Term IMU-838/MS Catalysts; Q1:23
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: Immunic, Inc.
Industry: Medical - Biomedical and Genetics
Company: Immunic, Inc.
Industry: Medical - Biomedical and Genetics
IMU-856 Displays Promising Efficacy/Safety in CD Supporting Its Advancement
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: Immunic, Inc.
Industry: Medical - Biomedical and Genetics
CALDOSE-1 Maintenance Data Hints at IMU-838''s Potential in GI; Pipeline Updates
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: Immunic, Inc.
Industry: Medical - Biomedical and Genetics
Company: Immunic, Inc.
Industry: Medical - Biomedical and Genetics
Q4/FY22 Financials; Potential Next Steps for IMU-935/Psoriasis in Q1:23
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A